linjc16/ctgov huggingface dataset:
Empirical Rescue Therapies of Helicobacter Pylori Infection

Study Overview
=================
Brief Summary
-----------------
The increase of antibiotic resistance to H. pylori causes failure of treatment. Furazolidone, amoxicillin and tetracycline are good candidates for rescue therapy since resistance to these three antimicrobials was rare. It is necessary to assess the efficacy and safety of these four bismuth-containing quadruple regimens with above antibiotics as empirical rescue therapies for H. pylori eradication.

Official Title
-----------------
Helicobacter Pylori Treatment

Conditions
-----------------
Functional Dyspepsia, Scarred Peptic Ulcer

Intervention / Treatment
-----------------
* Drug: Proton Pump Inhibitor
* Drug: Bismuth
* Drug: Metronidazole
* Drug: Tetracycline
* Drug: Furazolidone
* Drug: Amoxicillin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: H. pylori -positive patients with functional dyspepsia and scarred peptic ulcers who had previously failed one or more eradication regimens containing clarithromycin, metronidazole and/or amoxicillin. Exclusion Criteria: less than 18 years old, never receiving eradication treatment before, with previous gastric surgery, pregnancy, lactation, major systemic diseases, administration of antibiotics, bismuth, antisecretory drugs in the preceding 8 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: tetracycline/furazolidone<br>one of the four empirical rescue therapies | Drug: Proton Pump Inhibitor<br> <br> * Other names: Lansoprazole;Drug: Bismuth<br> <br> * Other names: Bismuth potassium citrate;Drug: Tetracycline<br> <br> Drug: Furazolidone<br> <br> |
| Experimental: amoxicillin/tetracycline<br>one of the four empirical rescue therapies | Drug: Proton Pump Inhibitor<br> <br> * Other names: Lansoprazole;Drug: Bismuth<br> <br> * Other names: Bismuth potassium citrate;Drug: Tetracycline<br> <br> Drug: Amoxicillin<br> <br> |
| Experimental: amoxicillin/furazolidone<br>one of the four empirical rescue therapies | Drug: Proton Pump Inhibitor<br> <br> * Other names: Lansoprazole;Drug: Bismuth<br> <br> * Other names: Bismuth potassium citrate;Drug: Furazolidone<br> <br> Drug: Amoxicillin<br> <br> |
| Active Comparator: tetracycline /metronidazole<br>Classical rescue therapy | Drug: Proton Pump Inhibitor<br> <br> * Other names: Lansoprazole;Drug: Bismuth<br> <br> * Other names: Bismuth potassium citrate;Drug: Metronidazole<br> <br> Drug: Tetracycline<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| eradication rate of H. pylori |  | 2 months |
Obesity and the Initiation of Knee Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
Healthy adults aged 20-60 of varying weights will participate in this minimally invasive study. There is one 4-hour appointment for which subjects are paid $120. The tests involve: 1 tube blood draw, 1 gait test (motion capture) and 1 MR of both knees.

Detailed Description
-----------------
The tests will be done at the VA and Stanford and are not dangerous or painful. They are designed to help us learn more about the relationship of excess weight on cartilage degradation by testing a biomarker in blood. Gait testing involves walking in a lab that is about 20 meters long about 20 times. MR involves lying in a tube for less than 1 hour.

Official Title
-----------------
Obesity and Initiation of Osteoarthritis

Conditions
-----------------
Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Adults aged 20-60 who have no history of LE surgery Healthy adults able to walk 30 minutes Healthy adults able to have MR Exclusion Criteria: Adults who have had LE surgery Adults cannot walk 30 minutes Adults who cannot tolerate MR Adults with osteoarthritis

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gait Knee Adduction Moment |  | baseline or first and only visit. | 
| Cartilage Thickness | Medial/lateral thickness ratio | baseline or first and only visit. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
obesity, arthritis
Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection

Study Overview
=================
Brief Summary
-----------------
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects host-cells via ACE2-receptors, which leads to pneumonia (COVID-19) but also can lead to myocarditis (acute myocardial injury) and chronic damage to the cardiovascular system. Therefore, cardiovascular protection may be necessary when treating patients with COVID-19 infection. This may especially be necessary in patients with cardiovascular diseases, risk factors, and co-medication.

Official Title
-----------------
Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection

Conditions
-----------------
Cardiovascular Diseases, Cardiovascular Risk Factor, SARS

Intervention / Treatment
-----------------
* Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with suspected SARS-CoV2/Covid-19 infection Exclusion Criteria: Unwillingness to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors|At inclusion, patients will be screened for pre-existing cardiovascular diseases and cardiovascular risk factors, as well as medication.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality | mortality of any cause | During 1 year follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 30-day mortality | mortality of any cause | Within 30 days after inclusion | 
| Major adverse cardiovascular events | Myocardial infarction, stroke, or CV death | During 1 year follow-up |
Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if certain drugs commonly used to treat multiple sclerosis have an effect on bone health.

Detailed Description
-----------------
There will be 60 female patients with MS at University of Kansas Medical Center (KUMC). They will be split into two groups: a Copaxone group and an Interferon (Avonex, Rebif, or Betaseron) group. Each group will be composed of 30 women matched for menopausal status. Each subject will be given a questionnaire assessing risk factors for low bone density. All patients will have a determination of an Expanded Disability Status Scale (EDSS), height and weight, medical history, and fracture history. All patients will undergo hip and spine dual x-ray absorptiometry (DEXA) and will have labs drawn to determine serum 25 hydroxyvitamin D, parathyroid hormone, ionized calcium, estradiol, bone-specific acetyl phosphatase, osteocalcin, and C-peptides.

Official Title
-----------------
Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis: A Pilot Study

Conditions
-----------------
Multiple Sclerosis, Low Bone Density

Intervention / Treatment
-----------------
* Drug: Copaxone
* Drug: Interferon-beta 1a
* Drug: Interferon-beta 1b


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female, age > 18 Able to understand and give informed consent Relapsing remitting multiple sclerosis (RRMS) Treatment with interferons or Copaxone for at least one year prior to study entry Exclusion Criteria: Known osteoporosis History of hypercalcemia Currently pregnant History of primary hyperparathyroidism, hyperthyroidism, or hypothyroidism Unstable medical condition Ongoing use of bisphosphonates

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients receive Copaxone | Drug: Copaxone<br>* 20 mg, subcutaneous injections, taken daily<br>* Other names: Glatiramer acetate;|
| 2<br>Patients receive interferons | Drug: Interferon-beta 1a<br>* 30 mcg injected intramuscularly, once weekly<br>* Other names: Avonex;Drug: Interferon-beta 1b<br>* .25 mg/day, taken every other day, subcutaneous injections<br>* Other names: Betaseron;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MS (Multiple Sclerosis)
Multicenter Observational Study of PSC and IgG4-SC in China

Study Overview
=================
Brief Summary
-----------------
The investigators aimed to collect demographic features and clinical outcomes in patients diagnosed with PSC and IgG4-SC by utilizing participants database from multiple medical centers across Mainland China. Cross-sectional studies will focus on characterizing clinical presentations and validating diagnostic and prognostic models on Chinese PSC and IgG4-SC patients.

Official Title
-----------------
Multicenter Study of Clinical Characteristics and Management of Primary Sclerosing Cholangitis and IgG4-related Sclerosing Cholangitis in China.

Conditions
-----------------
Primary Sclerosing Cholangitis, IgG4-related Sclerosing Cholangitis

Intervention / Treatment
-----------------
* Other: Only observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age above 18 years old, Male or Female, Patients admitted in our medical centers which met the PSC criteria according to The European Association for the Study of the Liver Clinical Practice Guidelines Management of cholestatic liver diseases in 2009; or patients diagnosed with IgG4-SC which met initially using the Japan Pancreas Society criteria and confirmed using HISORt criteria. Exclusion Criteria: Female subjects who is pregnant, breastfeeding or is considering being pregnant during the study; History of other malignancies, including hematological tumors, solid tumors except hepatobiliary system; History of infectious diseases, including hepatis A, B, C, E and tuberculosis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>patients diagnosed with Primary Sclerosing Cholangitis which met the PSC criteria according to The European Association for the Study of the Liver Clinical Practice Guidelines Management of cholestatic liver diseases in 2009. | Other: Only observation<br>* No intervention is needed.<br>|
| B<br>patients diagnosed with IgG4-related Sclerosing Cholangitis which met initially using the Japan Pancreas Society criteria and confirmed using HISORt criteria. | Other: Only observation<br>* No intervention is needed.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The percentage of new occurrence of decompensated liver related events, malignancies, liver transplantation and liver-related death caused by PSC and IgG4-SC | describe the characteristics and clinical outcomes of PSC and IgG4-SC patients among multiple medical centers in China | 1 year |
Excimer Light in Psoriasis

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine the standard tissue levels of SP and its receptor in lesional skin of psoriasis patients in both developing and stationary stages before and after excimer light therapy.

Official Title
-----------------
Excimer Light Effect on Neurogenic Inflammation in Developing Versus Stationary Psoriasis Lesions

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Device: Excimer light


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type of Psoriasis: plaque psoriasis. Less than 10% surface area. Exclusion Criteria: Erythrodermic psoriasis Pustular psoriasis Topical treatment for psoriasis for the past 2 weeks. Systemic retinoids in the last 2 years. Systemic treatments (including any drugs that affect SP level as Aprepitant) in the last 3 months. Contraindications to excimer light therapy (history of skin malignancy or precancerous conditions like xeroderma pigmentosum or photosensitivity)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Active psoriasis<br> | Device: Excimer light<br>* Excimer light sessions<br>|
| Active Comparator: Stable psoriasis<br> | Device: Excimer light<br>* Excimer light sessions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Excimer laser efficiency in active and stable psoriasis | Determine the clinical improvement using Local psoriasis severity index | through study completion, an average of 6 months | 
| Excimer laser efficiency on neurogenic inflammation | level of affection of the neurogenic inflammation in psoriasis lesions after using Excimer light therapy. Determine substance P and its receptor levels before and after therapy. | through study completion, an average of 6 months |
Arteriopathy and Endothelial Function

Study Overview
=================
Brief Summary
-----------------
To determine whether fruit juice might reverse endothelial dysfunction and whether this reversibility has a prognosis value

Official Title
-----------------
Endothelial Dysfunction Reversibility in Patients With Peripheral Arterial Disease

Conditions
-----------------
Peripheral Arterial Disease

Intervention / Treatment
-----------------
* Procedure: Fruit juice or placebo absorption


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Peripheral arteriopathy Stable cardio-respiratory status Exclusion Criteria: Dialysis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: fruit juice<br>300 mL of fruit juice | Procedure: Fruit juice or placebo absorption<br>* absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.<br>|
| Placebo Comparator: placebo<br>300 mL of fruit juice without polyphenols | Procedure: Fruit juice or placebo absorption<br>* absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endothelial function 1 hour after taking the juice |  | 1 hour after taking the juice | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship between reversibility of the endothelial function and the patient's prognosis at 3 years |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arteriopathy, endothelial function, fruit juice
Statistical Analysis of Vlagtwedde-Vlaardingen Data Set

Study Overview
=================
Brief Summary
-----------------
To determine the effects in early adulthood of asthma, increased bronchial responsiveness, markers of allergy and smoking on pulmonary function level and the effects of these same risk factors on subsequent decline in pulmonary function, because these early adult factors presumably profoundly influence the risk for chronic obstructive pulmonary disease.

Detailed Description
-----------------
DESIGN NARRATIVE: The questions studied included whether the above named risk factors reduced the maximally attained level of pulmonary function in early adulthood, foreshortened the postulated stability of level of pulmonary function between age 18 and 35 and/or unfavorably affected subsequent decline in level of pulmonary function. FEV1/h2, VC/h2 and FEV1/IVC were studied, using graphic smooth techniques and regression analyses techniques on both cross-sectional and longitudinal datasets. In addition, the investigators tested the hypothesis stating that early adult symptoms of asthma, increased bronchial responsiveness, markers of allergy influenced who became a smoker, influenced the amount smoked and/or influenced who stopped smoking relatively early in adult life, using logistic regression analyses and survival analyses. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Asthma, Lung Diseases, Obstructive, Chronic Obstructive Pulmonary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Adherence to Lumefantrine-Artemether

Study Overview
=================
Brief Summary
-----------------
This is a study of how well caregivers of children with malaria adhere to the recommended regimen for lumefantrine-artemether (LA). Children were randomly assigned to either a group receiving directly observed treatment in hospital or to a group treated at home by the routine caregiver (typically, patient's mother). Clinical/parasitologic, hematologic, pharmacologic and qualitative parameters were monitored over a 28-day follow-up period and are used to evaluate drug adherence.

Official Title
-----------------
Assessment of Adherence to a 6-Dose Regimen of Coartem for Treatment of Uncomplicated Malaria in Children Under 5 Years in Tanzania

Conditions
-----------------
Malaria, Uncomplicated

Intervention / Treatment
-----------------
* Drug: artemether-lumefantrine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: age < 5 years of age. axillary temperature >= 37.5oC unmixed infection with P. falciparum of between 1,000 and 250,000 asexual parasites/mm3 as determined by microscopic examination of thick, or thick and thin peripheral blood smears. parent/guardian's informed consent and willingness to participate in the study Exclusion criteria: any evidence of severe or complicated malaria that would require hospitalization for treatment. reported allergy to any antimalarial drugs, including artemisinin derivatives and sulfa drugs.

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 59 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: artemether-lumefantrine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
malaria, artemether-lumefantrine, co-artem, Tanzania, adherence